|
| Status |
Public on Dec 20, 2011 |
| Title |
breast, post AFI treatment (H19_1935) |
| Sample type |
RNA |
| |
|
| Source name |
Human breast, post AFI treatment
|
| Organism |
Homo sapiens |
| Characteristics |
type_of_rx: AFG
pre_or_post_treatment: post
response: SD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 57
baseline tumor size (cm): 5x5
patient id (to identify the 2 chips from the same patient): 19101935
|
| Treatment protocol |
After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
|
| Growth protocol |
N/A
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol extraction
|
| Label |
biotin
|
| Label protocol |
3' IVT express
|
| |
|
| Hybridization protocol |
Standard Affymetix protocol for 3' IVT design
|
| Scan protocol |
Scanner GCS3000 7G
|
| Description |
RE1_H19_1935_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
| Data processing |
Expression were estimated using BRB Array Tools software, GCRMA method
|
| |
|
| Submission date |
Nov 14, 2011 |
| Last update date |
Dec 20, 2011 |
| Contact name |
Suzanne Fuqua |
| Organization name |
Baylor College of Medicine
|
| Street address |
1 Baylor Plaza
|
| City |
Houston |
| State/province |
Texas |
| ZIP/Postal code |
77030 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE33658 |
A phase II neoadjuvant trial of anastrozole (A), fulvestrant (F) and gefitinib (I - iressa) in patients with newly diagnosed estrogen receptor positive breast cancer |
|
